ArticleJACS Au2026
DeepDOX1: A Dual-Drive Framework Integrating Deep Learning and First-Principles Quantum Chemistry for Drug-Protein Affinity Prediction.
Article in JACS Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, there has been a surge in artificial intelligence (AI)-based drug-protein (or pesticide-protein) affinity (DPA) prediction tools. The field has been primarily driven by evolving deep-learning architectures and increasingly complex representations, leading to a growing demand for training data sourced from limited experimental data. In this work, we present DeepDOX1, a dual-drive DPA prediction tool featuring the tight integration of a concise AI architecture and an interpretable, quantum chemistry-based representation of protein-ligand interactions. To be more specific, the first-principles quantum chemistry-generated features incorporating the interactions between the drug and the protein binding pocket allow a relatively simple convolutional neural network (CNN) model trained on a relatively small training set (9,938 binders) to exhibit exceptional generalization capabilities across extensive testing involving 1,281 binders. Notably, DeepDOX1 outperforms popular AI-based DPA prediction methods in the tests simulating real-world hit-to-lead optimization (HLO) scenarios and a highly challenging test set featuring covalent ligands, halogenated ligands, and metalloproteins, even though its training set does not contain any covalent ligands. To further validate its practical utility, we designed a series of novel covalent inhibitors targeting the diabetes target molecule
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.